Dr Alison Cave, MHRA chief safety officer, said: “It’s crucial that patients are aware of vital information about the medicines they’re taking.
“The new patient alert cards aim to raise awareness among men taking finasteride about the potential for psychiatric and sexual side effects, so they can make an informed decision about their treatment and know what to do if they experience these side effects.”
She said patients should “remember to always read the leaflet inside the pack”.
The MHRA is recommending that patients inform their doctors of any personal history of depression or suicidal thoughts before taking the drug and stop the treatment “immediately” if they are taking it for hair loss and develop symptoms, or “speak to their doctor urgently” if it is for an enlarged prostate.
Sexual dysfunction should also be discussed with a doctor if symptoms develop.
The MHRA also encouraged patients to show the patient alert card to friends and family as they “may not notice changes to their mood” themselves.
There were around 4.2 million NHS prescriptions for the drug in 2023, which suggests around 350,000 a month were taking the daily 5mg pill for an enlarged prostate.
It is not known how many people get the drug for hair loss on a private prescription but some clinics have reported an increase. It is only licensed by the MHRA for hair loss in 18 to 41-year-olds, and the treatment of enlarged prostates.
Sarah Carter is a health and wellness expert residing in the UK. With a background in healthcare, she offers evidence-based advice on fitness, nutrition, and mental well-being, promoting healthier living for readers.
